ARCH:TSXV
ACHFF:OTC
Home
About us
Our story, our approach
Our Science
Pipeline, research & publications
Our Key Platforms
MetaBlok™
Treating, organ injury caused by inflammation
AB569
Treatment for Respiratory Pseudomonas aeruginosa Infections
BORG
Peptide Solid Surface Interface
MetaMx™
Brain Tumor Initiating Cell Targeting
Our Publications
Peer-reviewed scientific publications
AB569
Brain Tumor Stem Cell Targeting
BORG Peptide Solid Surface Interface
Treatments for Inflammation
Our Team
Management & lead scientists
Our Management
Governance, Executive, Board of Directors and Advisors
Our Principal Scientists
Learn about the scientists behind our technologies
MetaBlok™ and MetaMx™
AB569 & Respiratory Pseudomonas
BORG Peptide
Treatments for Inflammation
Investor Hub
Investor relations, fundamentals
Fundamentals
Press Releases
Investor Information
Stock Performance
Reports and Filings
Management Discussion and Analysis
Annual and Quarterly Reports
Proxies and Information Circulars
Material Change Documents
Other SEDAR Filings
Contact Us
Other SEDAR Filings
Other SEDAR Filings 2021
Download PDF Documents
CEO FORM 52-109FV2 - Q1 2021
Acting CFO FORM 52-109FV2 - Q1 2021
CEO FORM 52-109FV2 - Q2 2021
Acting CFO FORM 52-109FV2 - Q2 2021
Other SEDAR Filings 2020
Download PDF Documents
CEO FORM 52-109FV2 - Q1 2020
Acting CFO FORM 52-109FV2 Certification of Interim Filings - Q1 2020
CEO FORM 52-109FV2-Q2 2020
Acting CFO FORM 52-109FV2 Certification of Interim Filings
CEO FORM 52-109FV2-Q3 2020
Acting CFO FORM 52-109FV2-Q3 2020
CEO FORM 52-109FV2 - Q4 2020
Acting CFO FORM 52-109FV2 Certification of Interim Filings - Q4 2020
Other SEDAR Filings 2019
Download PDF Documents
CEO FORM 52-109FV2 Certification of Interim Filings
Acting CFO FORM 52-109FV2 Certification of Interim Filings
CEO FORM 52-109FV2 Certification of Interim Filings
Acting CFO FORM 52-109FV2 Certification of Interim Filings
CEO FORM 52-109FV2 Certification of Interim Filings
Acting CFO FORM 52-109FV2 Certification of Interim Filings
CEO FORM 52-109FV2 Certification of Interim Filings
Acting CFO FORM 52-109FV2 Certification of Interim Filings
Other SEDAR Filings 2018
Download PDF Documents
Acting CFO Certification of Annual Filings 52-109fv1 CFO 2018-01-29
CEO Certification of Annual Filings 52-109fv1 CEO 2018-01-29
Acting CFO FORM 52-109FV2 - Q3 - 2018-08-29
CEO FORM 52-109FV2 - Q3 - 2018-08-29
Other SEDAR Filings 2017
Download PDF Documents
NI Card 2017-03-07
Acting CFO Certification of Annual Filings 52-109fv1 CFO 2017-01-30
CEO Certification of Annual Filings 52-109fv1 CEO 2017-01-30
Acting CFO Certification of Annual Filings 52-109fv1 CFO 2017-03-01
CEO Certification of Annual Filings 52-109fv1 CEO 2017-03-01
Other 2017-03-07
Other SEDAR Filings 2016
Download PDF Documents
Certification of Annual Filings 52-109fv1 CEO 2016-01-28
Certification of Annual Filings 52-109fv1 CFO 2016-01-28
Q3 Certification of Annual Filings 52-109fv1 Acting CFO 2016-08-30
Q3 Certification of Annual Filings 52-109fv1 CEO 2016-08-30
Other SEDAR Filings 2015
Download PDF Documents
Certification of Interim Filings 52-109fv2 CEO 2015-01-28
Certification of Interim Filings 52-109fv2 CFO 2015-01-28
Certification of Interim Filings 52-109fv2 CEO 2015-03-02
Certification of Interim Filings 52-109fv2 CFO 2015-03-02
Certification of Interim Filings 52-109fv2 CEO 2015-06-01
Certification of Interim Filings 52-109fv2 CFO 2015-06-01
Certification of Interim Filings 52-109fv2 CEO 2015-08-31
Certification of Interim Filings 52-109fv2 CFO 2015-08-31
Other SEDAR Filings 2014
Download PDF Documents
Certification of Interim Filings 52-109fv2 CEO 2014-01-28
Certification of Interim Filings 52-109fv2 CFO 2014-01-28
Certification of Interim Filings 52-109fv2 CEO 2014-03-03
Certification of Interim Filings 52-109fv2 CFO 2014-03-03
Certificate Re Dissemination to Shareholders 2014-03-05
Form of Proxy 2014-03-05
Other 2014-03-05
Other 2014-03-07
Certification of Interim Filings 52-109fv2 CEO 2014-05-30
Certification of Interim Filings 52-109fv2 CFO 2014-05-30
Other SEDAR Filings 2013
Download PDF Documents
Certification of Interim Filings 52-109fv2 CEO 2013-01-29
Certification of Interim Filings 52-109fv2 CFO 2013-01-29
Certification of Interim Filings 52-109fv2 CEO 2013-03-01
Certification of Interim Filings 52-109fv2 CFO 2013-03-01
Certification Re Dissemination to Shareholders 2013-03-08
Other 2013-03-08
Certification of Interim Filings 52-109fv2 CEO 2013-05-30
Certification of Interim Filings 52-109fv2 CFO 2013-05-30
Certification of Interim Filings 52-109fv2 CEO 2013-08-29
Certification of Interim Filings 52-109fv2 CFO 2013-08-29
Form of Proxy 2013-03-08
Other SEDAR Filings 2012
Download PDF Documents
Certification of Interim Filings 52-109fv2 CEO 2012-01-30
Certification of Interim Filings 52-109fv2 CFO 2012-01-30
Certification of Interim Filings 52-109fv2 CEO 2012-02-29
Certification of Interim Filings 52-109fv2 CFO 2012-02-29
Certificate Re Dissemination to Shareholders 2012-03-08
Form of Proxy 2012-03-08
Other 2012-03-08
Certification of Interim Filings 52-109fv2 CEO 2012-05-30
Certification of Interim Filings 52-109fv2 CFO 2012-05-30
Certification of Interim Filings 52-109fv2 CEO 2012-08-29
Certification of Interim Filings 52-109fv2 CFO 2012-08-29
Certification of Refiled Interim Filings 52-109f2r CEO 2012-10-01
Certification of Refiled Interim Filings 52-109f2r CFO 2012-10-01
Recent News
June 10th 2021
Arch Biopartners Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediated Organ Inflammation
Read More
May 4th 2021
Arch Biopartners Completes Enrollment in Phase II Trial of Metablok (LSALT Peptide) in Hospitalized Patients with COVID-19
Read More
See All
Subscribe to News
Other SEDAR Filings
Home
About us
Our Science
--Our Key Platforms
---MetaBlok™
---AB569
---BORG
---MetaMx™
--Our Publications
---AB569
---Brain Tumor Stem Cell Targeting
---BORG Peptide Solid Surface Interface
---Treatments for Inflammation
Our Team
--Our Management
--Our Principal Scientists
---MetaBlok™ and MetaMx™
---AB569 & Respiratory Pseudomonas
---BORG Peptide
---Treatments for Inflammation
Investor Hub
--Fundamentals
---Press Releases
---Investor Information
---Stock Performance
--Reports and Filings
---Management Discussion and Analysis
---Annual and Quarterly Reports
---Proxies and Information Circulars
---Material Change Documents
---Other SEDAR Filings
Contact Us
Home
About us
Our Science
Our Key Platforms
MetaBlok™
AB569
BORG
MetaMx™
Our Publications
AB569
Brain Tumor Stem Cell Targeting
BORG Peptide Solid Surface Interface
Treatments for Inflammation
Our Team
Our Management
Our Principal Scientists
MetaBlok™ and MetaMx™
AB569 & Respiratory Pseudomonas
BORG Peptide
Treatments for Inflammation
Investor Hub
Fundamentals
Press Releases
Investor Information
Stock Performance
Reports and Filings
Management Discussion and Analysis
Annual and Quarterly Reports
Proxies and Information Circulars
Material Change Documents
Other SEDAR Filings
Contact Us